Parnell Pharmaceuticals Holdings Ltd
PARNF · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $34,166 | $30,000 | $28,994 | $26,548 |
| % Growth | 13.9% | 3.5% | 9.2% | – |
| Cost of Goods Sold | $14,901 | $12,481 | $11,604 | $11,025 |
| Gross Profit | $19,265 | $17,520 | $17,390 | $15,523 |
| % Margin | 56.4% | 58.4% | 60% | 58.5% |
| R&D Expenses | $2,832 | $1,807 | $1,388 | $586 |
| G&A Expenses | $8,707 | $6,788 | $7,644 | $6,427 |
| SG&A Expenses | $15,086 | $13,741 | $16,026 | $11,668 |
| Sales & Mktg Exp. | $6,379 | $6,953 | $6,159 | $5,240 |
| Other Operating Expenses | $0 | $0 | $0 | -$10 |
| Operating Expenses | $17,918 | $20,843 | $16,952 | $12,104 |
| Operating Income | $1,347 | $3,778 | $1,363 | $2,606 |
| % Margin | 3.9% | 12.6% | 4.7% | 9.8% |
| Other Income/Exp. Net | -$2,766 | -$17,017 | -$6,924 | -$3,082 |
| Pre-Tax Income | -$1,419 | -$15,046 | -$6,949 | $337 |
| Tax Expense | $1 | $15 | $233 | $207 |
| Net Income | -$1,420 | -$15,061 | -$7,182 | $130 |
| % Margin | -4.2% | -50.2% | -24.8% | 0.5% |
| EPS | -0.049 | -0.81 | -0.4 | 0.007 |
| % Growth | 94% | -102.5% | -5,680.4% | – |
| EPS Diluted | -0.049 | -0.81 | -0.4 | 0.007 |
| Weighted Avg Shares Out | 28,962 | 18,549 | 18,023 | 18,083 |
| Weighted Avg Shares Out Dil | 28,962 | 18,550 | 18,024 | 18,084 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,591 | $11,723 | $7,387 | $4 |
| Interest Expense | $0 | $0 | $0 | $6,188 |
| Depreciation & Amortization | $1,824 | $451 | $1,035 | $2,653 |
| EBITDA | $6,002 | $4,229 | $2,399 | $5,260 |
| % Margin | 17.6% | 14.1% | 8.3% | 19.8% |